The Top Reasons Bioprocessing CDMOs Lose Bids
Source: Life Science Leader
By Industry Standard Research
Respondents continue to report that service providers primarily lose bids for bioprocessing efforts due to regulatory violations/FDA form 483 warnings (49%), their inability to meet required timelines (48%), and high cost (47%). Roughly one-fifth of this year’s survey participants listed regulatory violations and timeline shortcomings as the main reasons why a CDMO is not selected (23% and 19%, respectively).
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more